A Study to Assess APO866 for the Treatment of Advanced Melanoma
A Multi-centre, Two-stage, Open Label Phase II Study to Assess the Efficacy and Safety of APO866 in the Treatment of Patients With Advanced Melanoma.
Sponsor: Valerio Therapeutics
Listed as NCT00432107, this PHASE2 trial focuses on Melanoma and remains completed. Sponsored by Valerio Therapeutics, it has been updated 7 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jan 2024 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Jul 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Valerio Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .